Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer
Anne Favret, MD on FDA Approval of Capivasertib (Truqap) in Combination with Fulvestrant for HR-positive, HER2-negative Breast Cancer
Source: onclive.com
Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Anne Favret, MD on FDA Approval of Capivasertib (Truqap) in Combination with Fulvestrant for HR-positive, HER2-negative Breast Cancer
U.S. Congressman Greg Murphy recently introduced a bill that could make an enormous difference for patients while protecting hundreds of thousands of good-paying North Carolina jobs.
The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in...